Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:33 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524768 | NSE: EMMESSA

Emmessar Biotech & Nutrition Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹21.15Overvalued by 16.40%vs CMP ₹25.30

P/E (38.3) × ROE (4.2%) × BV (₹16.00) × DY (2.00%)

₹15.96Overvalued by 36.92%vs CMP ₹25.30
MoS: -58.5% (Negative)Confidence: 59/100 (Moderate)Models: 1 Under, 7 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹19.6225%Over (-22.5%)
Graham NumberEarnings₹15.4118%Over (-39.1%)
Earnings PowerEarnings₹8.5612%Over (-66.2%)
DCFCash Flow₹6.5315%Over (-74.2%)
Net Asset ValueAssets₹16.068%Over (-36.5%)
Earnings YieldEarnings₹6.608%Over (-73.9%)
ROCE CapitalReturns₹47.1210%Under (+86.2%)
Revenue MultipleRevenue₹1.226%Over (-95.2%)
Consensus (8 models)₹15.96100%Overvalued
Key Drivers: ROE 4.2% is below cost of equity. | Wide model spread (₹1–₹47) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -7.2%

*Investments are subject to market risks

Investment Snapshot

49
Emmessar Biotech & Nutrition Ltd scores 49/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health69/100 · Strong
ROCE 12.6% GoodROE 4.2% WeakD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
Promoter holding at 59.5% Stable
Earnings Quality50/100 · Moderate
OPM contracting (-159% → -174%) DecliningWorking capital: 36 days (improving) Efficient
Quarterly Momentum15/100 · Weak
Revenue (4Q): -38% YoY DecliningProfit (4Q): -50% YoY DecliningOPM: -377.8% (down 97.8% YoY) Margin pressure
Industry Rank55/100 · Moderate
P/E 38.3 vs industry 82.7 Cheaper than peersROCE 12.6% vs industry 14.0% AverageROE 4.2% vs industry 10.7% Below peers3Y sales CAGR: 19% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Emmessar Biotech & Nutrition Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
40/100
Moderate
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 38.3 vs Ind 82.7 | ROCE 12.6% | ROE 4.2% | CFO/NP N/A
Balance Sheet Stress
0/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.00x | IntCov 0.0x | Current 3.85x | Borrow/Reserve 0.00x
Cash Flow Reliability
29/100
Weak
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹0 Cr | CFO/NP N/A
Ownership Accumulation
0
Neutral
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII N/A | DII 0.00 pp | Prom 0.00 pp
Business Momentum
+100
Stable
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales 0.0% | Q NP +9.1% | Q OPM +33.3 pp
Derived FieldValueHow it is derived
Valuation Gap %-36.9%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.00xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII ChangeN/ALatest FII% minus previous FII%
DII Change0.00 ppLatest DII% minus previous DII%
Promoter Change0.00 ppLatest promoter% minus previous promoter%
Shareholder Count Change-106Latest shareholder count minus previous count
Quarterly Sales Change0.0%Latest quarter sales vs previous quarter sales
Quarterly Profit Change+9.1%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change+33.3 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:33 am

Market Cap 12.6 Cr.
Current Price 25.3
Intrinsic Value₹15.96
High / Low 42.9/18.4
Stock P/E38.3
Book Value 16.0
Dividend Yield0.00 %
ROCE12.6 %
ROE4.23 %
Face Value 10.0
PEG Ratio-5.30

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Emmessar Biotech & Nutrition Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Emmessar Biotech & Nutrition Ltd 12.6 Cr. 25.3 42.9/18.438.3 16.00.00 %12.6 %4.23 % 10.0
Archean Chemical Industries Ltd 7,175 Cr. 581 728/48039.2 1570.52 %16.0 %12.0 % 2.00
Deepak Nitrite Ltd 18,443 Cr. 1,352 2,174/1,28034.0 4040.55 %16.3 %13.4 % 2.00
Vishnu Chemicals Ltd 3,347 Cr. 497 596/33624.3 1490.06 %18.1 %15.5 % 2.00
Alufluoride Ltd 333 Cr. 425 491/37614.0 1440.71 %23.6 %20.8 % 10.0
Industry Average4,204.50 Cr338.2082.73156.250.59%13.95%10.65%6.18

All Competitor Stocks of Emmessar Biotech & Nutrition Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 0.430.320.070.080.330.080.080.340.100.100.090.090.09
Expenses 0.600.480.350.300.540.470.360.420.380.430.360.460.43
Operating Profit -0.17-0.16-0.28-0.22-0.21-0.39-0.28-0.08-0.28-0.33-0.27-0.37-0.34
OPM % -39.53%-50.00%-400.00%-275.00%-63.64%-487.50%-350.00%-23.53%-280.00%-330.00%-300.00%-411.11%-377.78%
Other Income 0.440.420.460.530.530.480.460.510.430.610.530.540.49
Interest 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation 0.020.020.020.020.020.020.020.020.020.020.020.030.03
Profit before tax 0.250.240.160.290.300.070.160.410.130.260.240.140.12
Tax % 108.00%20.83%68.75%31.03%56.67%-285.71%43.75%31.71%84.62%126.92%25.00%21.43%8.33%
Net Profit -0.020.200.050.200.130.270.090.280.02-0.070.170.110.12
EPS in Rs -0.040.400.100.400.260.540.180.560.04-0.140.340.220.24

Last Updated: March 3, 2026, 10:04 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 4:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1.372.191.982.611.270.633.406.990.361.020.560.610.37
Expenses 1.432.342.662.381.671.273.816.151.261.711.641.561.68
Operating Profit -0.06-0.15-0.680.23-0.40-0.64-0.410.84-0.90-0.69-1.08-0.95-1.31
OPM % -4.38%-6.85%-34.34%8.81%-31.50%-101.59%-12.06%12.02%-250.00%-67.65%-192.86%-155.74%-354.05%
Other Income 0.090.060.030.981.251.011.211.471.921.751.992.012.17
Interest 0.000.000.000.010.000.000.000.000.000.000.000.000.00
Depreciation 0.200.070.030.010.050.080.060.060.090.090.100.100.10
Profit before tax -0.17-0.16-0.681.190.800.290.742.250.930.970.810.960.76
Tax % 82.35%-25.00%-30.88%0.00%-15.00%-82.76%-2.70%36.00%48.39%47.42%7.41%66.67%
Net Profit -0.31-0.12-0.471.190.910.530.751.450.480.500.750.320.33
EPS in Rs -0.62-0.24-0.942.381.821.061.502.900.961.001.500.640.66
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)61.29%-291.67%353.19%-23.53%-41.76%41.51%93.33%-66.90%4.17%50.00%-57.33%
Change in YoY Net Profit Growth (%)0.00%-352.96%644.86%-376.72%-18.23%83.27%51.82%-160.23%71.06%45.83%-107.33%

Emmessar Biotech & Nutrition Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-12%
5 Years:-29%
3 Years:19%
TTM:11%
Compounded Profit Growth
10 Years:17%
5 Years:-20%
3 Years:-13%
TTM:-42%
Stock Price CAGR
10 Years:10%
5 Years:15%
3 Years:2%
1 Year:-35%
Return on Equity
10 Years:16%
5 Years:11%
3 Years:7%
Last Year:4%

Last Updated: September 5, 2025, 3:21 pm

Balance Sheet

Last Updated: March 3, 2026, 12:56 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 5.005.005.005.005.005.005.005.005.005.005.005.005.00
Reserves -3.42-3.62-4.09-2.91-2.01-1.49-0.730.701.171.672.412.713.00
Borrowings 0.000.000.000.000.000.070.000.000.000.080.110.000.00
Other Liabilities 0.651.031.361.130.921.591.862.111.041.191.231.511.52
Total Liabilities 2.232.412.273.223.915.176.137.817.217.948.759.229.52
Fixed Assets 1.581.420.730.722.251.991.911.862.072.001.911.811.77
CWIP 0.000.000.000.800.000.000.000.000.000.000.000.000.00
Investments 0.010.010.010.010.010.010.010.010.010.010.010.010.01
Other Assets 0.640.981.531.691.653.174.215.945.135.936.837.407.74
Total Assets 2.232.412.273.223.915.176.137.817.217.948.759.229.52

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0.00-0.010.750.740.391.030.472.270.380.640.22
Cash from Investing Activity + 0.000.00-0.74-0.69-0.37-1.060.01-2.61-0.55-0.64-0.23
Cash from Financing Activity + 0.000.000.000.000.000.000.000.000.000.000.00
Net Cash Flow 0.00-0.010.010.050.01-0.030.48-0.34-0.170.000.00
Free Cash Flow 0.00-0.01-0.06-0.040.391.030.471.960.350.640.22
CFO/OP 0%7%343%-198%-61%-251%68%-284%-46%-57%-25%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-0.06-0.15-0.680.23-0.40-0.71-0.410.84-0.90-0.77-1.19-0.95

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 45.296.6766.365.598.6223.173.22141.5110.143.5813.0411.97
Inventory Days 267.67335.80136.88121.6752.142,049.62272.567.24196.54127.75164.25230.53
Days Payable 121.67150.8776.0476.045.791,628.46189.6151.7056.150.0018.250.00
Cash Conversion Cycle 191.29191.60127.2051.2254.97444.3386.1897.05150.52131.33159.04242.49
Working Capital Days 29.3138.3322.1285.31175.31457.7030.0679.37-60.83114.5191.2535.90
ROCE %-9.60%-10.81%-39.30%80.00%31.50%17.66%25.48%45.14%15.67%15.02%11.35%12.61%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 59.08%59.33%59.53%59.53%59.53%59.53%59.53%59.53%59.53%59.53%59.53%59.53%
DIIs 0.19%0.19%0.19%0.19%0.19%0.19%0.19%0.19%0.19%0.19%0.19%0.19%
Public 40.73%40.46%40.27%40.28%40.26%40.27%40.27%40.28%40.27%40.28%40.28%40.27%
No. of Shareholders 6,9336,8746,8226,8447,1466,9006,9367,1867,1807,1737,3507,244

Shareholding Pattern Chart

No. of Shareholders

Emmessar Biotech & Nutrition Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 0.611.480.990.942.88
Diluted EPS (Rs.) 0.611.480.990.942.88
Cash EPS (Rs.) 0.821.701.201.143.02
Book Value[Excl.RevalReserv]/Share (Rs.) 15.4314.8213.3412.3511.41
Book Value[Incl.RevalReserv]/Share (Rs.) 15.4314.8213.3412.3511.41
Revenue From Operations / Share (Rs.) 1.221.112.040.7313.99
PBDIT / Share (Rs.) 2.111.822.122.054.63
PBIT / Share (Rs.) 1.921.631.941.864.51
PBT / Share (Rs.) 1.921.631.941.864.51
Net Profit / Share (Rs.) 0.631.501.010.952.90
PBDIT Margin (%) 172.92163.94104.05280.5433.07
PBIT Margin (%) 156.94146.3694.86255.2432.25
PBT Margin (%) 156.85146.3694.86255.2432.25
Net Profit Margin (%) 51.75135.0149.43130.2520.73
Return on Networth / Equity (%) 4.1010.127.557.7025.43
Return on Capital Employeed (%) 10.969.8612.8513.5335.20
Return On Assets (%) 3.428.576.346.5818.57
Total Debt / Equity (X) 0.000.010.010.000.00
Asset Turnover Ratio (%) 0.060.060.130.041.00
Current Ratio (X) 15.6713.5614.1414.733.85
Quick Ratio (X) 15.4113.3813.8214.523.80
Inventory Turnover Ratio (X) 5.740.560.670.244.14
Interest Coverage Ratio (X) 1760.670.000.000.000.00
Interest Coverage Ratio (Post Tax) (X) 528.000.000.000.000.00
Enterprise Value (Cr.) 8.318.787.289.164.87
EV / Net Operating Revenue (X) 13.6115.817.1425.090.69
EV / EBITDA (X) 7.879.646.878.942.11
MarketCap / Net Operating Revenue (X) 24.8526.7412.1637.651.05
Price / BV (X) 1.972.011.862.231.29
Price / Net Operating Revenue (X) 24.8726.7512.1637.671.05
EarningsYield 0.020.050.040.030.19

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Emmessar Biotech & Nutrition Ltd. is a Public Limited Listed company incorporated on 17/03/1992 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24110MH1992PLC065942 and registration number is 065942. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company's Total Operating Revenue is Rs. 0.61 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Chemicals - Inorganic - OthersPlot No.T-3/2, Raigad District Maharashtra 410208Contact not found
Management
NamePosition Held
Mr. Srinivasa Raghavan Mathurakavi AyyangarManaging Director
Mr. Jeyavel B NadarExecutive Director
Dr.(Mrs.) Sarada S RaghavanNon Executive Director
Dr.(Mrs.) Anuradha S RaghavanNon Executive Director
Mr. Milind Sitaram DesaiInd. Non-Executive Director
Mr. Veeraraghavan RanganathanInd. Non-Executive Director
Mr. Dinesh Kumar DeoraInd. Non-Executive Director

FAQ

What is the intrinsic value of Emmessar Biotech & Nutrition Ltd and is it undervalued?

As of 07 April 2026, Emmessar Biotech & Nutrition Ltd's intrinsic value is ₹15.96, which is 36.92% lower than the current market price of ₹25.30, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (4.23 %), book value (₹16.0), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Emmessar Biotech & Nutrition Ltd?

Emmessar Biotech & Nutrition Ltd is trading at ₹25.30 as of 07 April 2026, with a FY2026-2027 high of ₹42.9 and low of ₹18.4. The stock is currently in the middle of its 52-week range. Market cap stands at ₹12.6 Cr..

How does Emmessar Biotech & Nutrition Ltd's P/E ratio compare to its industry?

Emmessar Biotech & Nutrition Ltd has a P/E ratio of 38.3, which is below the industry average of 82.73. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Emmessar Biotech & Nutrition Ltd financially healthy?

Key indicators for Emmessar Biotech & Nutrition Ltd: ROCE of 12.6 % is moderate; ROE of 4.23 % is below ideal levels (industry average: 10.65%). Dividend yield is 0.00 %.

Is Emmessar Biotech & Nutrition Ltd profitable and how is the profit trend?

Emmessar Biotech & Nutrition Ltd reported a net profit of ₹0 Cr in Mar 2025 on revenue of ₹1 Cr. Compared to ₹0 Cr in Mar 2022, the net profit shows a declining trend.

Does Emmessar Biotech & Nutrition Ltd pay dividends?

Emmessar Biotech & Nutrition Ltd has a dividend yield of 0.00 % at the current price of ₹25.30. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Emmessar Biotech & Nutrition Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports